The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,003
A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
Gautschi, O. P., Pauli, C., Strobel, K., Hirschmann, A., Printzen, G., Aebi, S. P., & Diebold, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182629903 · Cited by 141
Fibroblast-mediated drug resistance in cancer
Paraiso, K. H. T., & Smalley, K. S. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.018 · Cited by 147
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies, A. M., & Long, G. V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70072-5 · Cited by 145
Bepler, G., Williams, C. C., Schell, M. J., Chen, W., Zheng, Z., Simon, G. R., Gadgeel, S. M., Zhao, X., Schreiber, F. J., Brahmer, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9783 · Cited by 141
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Self-citationMolecular biology of normal melanocytes and melanoma cells
Bandarchi, B., Jabbari, C., Vedadi, A., & Navab, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201471 · Cited by 145
Anderson, S., Bloom, K. J., Vallera, D. U., Rueschoff, J., Meldrum, C. J., Schilling, R., Kovach, B., Lee, J. R.-J., Ochoa, P., Langland, R., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0505-oa · Cited by 139
Self-citationBRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 139
Directed Phenotype Switching as an Effective Antimelanoma Strategy
Sáez‐Ayala, M., Montenegro, M. F., Sánchez‐del‐Campo, L., Fernández-Pérez, M. P., Chazarra, S., Freter, R., Middleton, M. R., Piñero, A., Cabezas‐Herrera, J., Goding, C. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.009 · Cited by 139
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 135
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Niezgoda, A., Niezgoda, P., & Czajkowski, R. (2015) · BioMed Research International · doi:10.1155/2015/851387 · Cited by 138
Molecular drivers of cellular metabolic reprogramming in melanoma
Abildgaard, C., & Guldberg, P. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.12.007 · Cited by 138
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Genomic landscape of intracranial meningiomas
Bi, W. L., Abedalthagafi, M., Horowitz, P. M., Agarwalla, P. K., Mei, Y., Aizer, A. A., Brewster, R., Dunn, G. P., Al‐Mefty, O., Alexander, B. M., et al. (2016) · Journal of neurosurgery · doi:10.3171/2015.6.jns15591 · Cited by 131
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 134
Self-citationJohnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D. E., Peters, S., Rimoldi, D., & Michielin, O. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0661 · Cited by 130
Self-citationSánchez‐Laorden, B. L., Virós, A., Girotti, M. R., Pedersen, M., Saturno, G., Zambon, A., Niculescu‐Duvaz, D., Turajlic, S., Hayes, A. J., Gore, M. E., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004815 · Cited by 131
Ascierto, P. A., Simeone, E., Giannarelli, D., Grimaldi, A. M., Romano, A., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-107 · Cited by 131
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 130
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ
Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3461 · Cited by 126
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Clinical translation of nuclear export inhibitors in cancer
Senapedis, W. T., Baloglu, E., & Landesman, Y. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.005 · Cited by 129
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 132
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 124
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 131
Molzan, M., Kasper, S., Röglin, L., Skwarczynska, M., Sassa, T., Inoue, T., Breitenbuecher, F., Ohkanda, J., Kato, N., Schüler, M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4003464 · Cited by 123
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R. L., Riemenschneider, K., Slesur, L., Chen, S., Johnson, C. A., Yang, J., Blevins, A., Yan, C. W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 123
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Identification of secreted proteins that reflect autophagy dynamics within tumor cells
Kraya, A., Piao, S., Xu, X., Zhang, G., Herlyn, M., Gimotty, P. A., Levine, B., Amaravadi, R. K., & Speicher, D. W. (2014) · Autophagy · doi:10.4161/15548627.2014.984273 · Cited by 126
Self-citationData Set for Pathology Reporting of Cutaneous Invasive Melanoma
Scolyer, R. A., Judge, M. J., Evans, A. T., Frishberg, D. P., Prieto, V. G., Thompson, J. F., Trotter, M. J., WALSH, M. Y., Walsh, N. M. G., & Ellis, D. W. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31829d7f35 · Cited by 119
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 123
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Callahan, M. K., Masters, G. R., Pratilas, C. A., Ariyan, C. E., Katz, J. B., Kitano, S., Russell, V., Gordon, R. A., Vyas, S., Yuan, J. D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0160 · Cited by 116
Sinha, R., Edmonds, K., Newton‐Bishop, J., Gore, M. E., Larkin, J., & Fearfield, L. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12010 · Cited by 116
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Self-citationTrial Watch: Peptide-based anticancer vaccines
Pol, J. G., Bloy, N., Buqué, A., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974411 · Cited by 121
BRAF inhibitor activity in V600R metastatic melanoma
Klein, O., Clements, A., Menzies, A. M., O'Toole, S. A., Kefford, R. F., & Long, G. V. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.004 · Cited by 114
Self-citationEndris, V., Penzel, R., Warth, A., Muckenhuber, A., Schirmacher, P., Stenzinger, A., & Weichert, W. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.06.002 · Cited by 113
Nardi, V., Sadow, P. M., Juric, D., Zhao, S. D., Cosper, A. K., Bergethon, K. E., Scialabba, V. L., Batten, J. M., Borger, D. R., Iafrate, A. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1842 · Cited by 113
Self-citationMetaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Kim, S. Y., Kim, S., Hahn, H. J., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1113 · Cited by 113
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H., & Amaravadi, R. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.003 · Cited by 113
Self-citationNectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
Bevelacqua, V., Bevelacqua, Y., Candido, S., Skarmoutsou, E., Amoroso, A., Guarneri, C., Strazzanti, A., Gangemi, P., Mazzarino, M. C., D’Amico, F., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.594 · Cited by 114
BRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 113
Modeling Melanoma In Vitro and In Vivo
Beaumont, K. A., Mohana‐Kumaran, N., & Haass, N. K. (2013) · Healthcare · doi:10.3390/healthcare2010027 · Cited by 112
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers
Božić, I., & Nowak, M. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412075111 · Cited by 114
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 120
Gouda, M. A., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100788 · Cited by 115
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
Johnson, D. B., Saranga‐Perry, V., Lavin, P., Burnette, W. B., Clark, S. W., Uskavitch, D., Wallace, D. E., Dickson, M. A., Kudchadkar, R. R., & Sosman, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1683 · Cited by 111
Self-citationAllen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 115
Laikova, K. V., Oberemok, V. V., Krasnodubets, A. M., Gal’chinsky, N. V., Useinov, R. Z., Novikov, I. A., Temirova, Z. Z., Владимирович, Г. М., Shved, N. A., Kumeiko, V. V., et al. (2019) · Molecules · doi:10.3390/molecules24081516 · Cited by 119
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationOstrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 115
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 116
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 115
Élez, E., Ros, J., Navarro, J. F., Villacampa, G. J., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01976-z · Cited by 111
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
Cooper, Z. A., Frederick, D. T., Juneja, V. R., Sullivan, R. J., Lawrence, D. P., Piris, A., Sharpe, A. H., Fisher, D. E., Flaherty, K. T., & Wargo, J. A. (2013) · OncoImmunology · doi:10.4161/onci.26615 · Cited by 109
Self-citationGenotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z. Z., Chakraborty, A. K., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 114
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Mechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 112
Challenging resistance mechanisms to therapies for metastatic melanoma
Tentori, L., Lacal, P. M., & Graziani, G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.003 · Cited by 114
Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J., Jouary, T., & Merlio, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070826 · Cited by 108
Sharma, A., Shah, S. R., Illum, H., & Dowell, J. E. (2012) · Drugs · doi:10.2165/11640870-000000000-00000 · Cited by 108
Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
van der Noll, R., Leijen, S., Neuteboom, G. H. G., Beijnen, J. H., & Schellens, J. H. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.003 · Cited by 106
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications
Bi, W. L., Zhang, M., Wu, W. W., Mei, Y., & Dunn, I. F. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00040 · Cited by 106
McEvoy, A. C., Warburton, L., Al‐Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., Khattak, M. A., Meniawy, T. M., Millward, M., Ziman, M. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4637-6 · Cited by 107
Penman, C. L., Faulkner, C., Lowis, S. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00054 · Cited by 107
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Vemurafenib and radiation therapy in melanoma brain metastases
Narayana, A., Mathew, M., Tam, M. M., Kannan, R., Madden, K. M., Golfinos, J. G., Parker, E. C., Ott, P. A., & Pavlick, A. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1127-1 · Cited by 105
Self-citationTargeting Oncogenic Drivers and the Immune System in Melanoma
McArthur, G. A., & Ribas, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 108
Self-citationClinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L., Chen, G., Haley, L. M., Illei, P. B., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 105
Mitochondrial Respiration - An Important Therapeutic Target in Melanoma
de Moura, M. B., Vincent, G., Fayewicz, S. L., Bateman, N. W., Hood, B. L., Sun, M., Suhan, J. P., Duensing, S. M., Yin, Y., Sander, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040690 · Cited by 105
Self-citationPayne, R., Glenn, L. A., Hoen, H. M., Richards, B., Smith, J. W., Lufkin, R. B., Crocenzi, T. S., Urba, W. J., & Curti, B. D. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-13 · Cited by 105
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 108
Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., Shinn, L., Kelley, M. C., Joseph, R. W., & Sosman, J. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0092 · Cited by 104
Self-citationBabiker, H. M., McBride, A., Newton, M., Boehmer, L., Drucker, A., Gowan, M., Cassagnol, M., Camenisch, T. D., Anwer, F., & Hollands, J. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.014 · Cited by 104
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115153 · Cited by 107
Robertson, S., Hyder, O. N., Dodson, R. M., Nayar, S. K., Poling, J., Beierl, K. F., Eshleman, J. R., Lin, M., Pawlik, T. M., & Anders, R. A. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.07.026 · Cited by 104
Bucheit, A. D., Syklawer, E., Jakob, J. A., Bassett, R. L., Curry, J. L., Gershenwald, J. E., Kim, K. B., Hwu, P., Lazar, A. J., & Davies, M. A. (2013) · Cancer · doi:10.1002/cncr.28306 · Cited by 107
Self-citationOtt, P. A., Henry, T., Baranda, S. J., Frleta, D., Manches, O., Bogunovic, D., & Bhardwaj, N. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1389-z · Cited by 106
Bayesian basket trial design with exchangeability monitoring
Hobbs, B. P., & Landin, R. (2018) · Statistics in Medicine · doi:10.1002/sim.7893 · Cited by 103
Dahal, U., Le, K., & Gupta, M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000580 · Cited by 106
BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chen, D., Zhang, L.-Q., Huang, J.-F., Liu, K., Chuai, Z.-R., Yang, Z., Wang, Y., Shi, D., Liu, Q., Huang, Q. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101354 · Cited by 102
Cui, C., Mao, L., Chi, Z., Si, L., Sheng, X., Kong, Y., Li, S., Lian, B., Gu, K., Tao, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.79 · Cited by 102
Stark, M. S., Klein, K., Weide, B., Haydu, L. E., Pflugfelder, A., Tang, Y., Palmer, J. M., Whiteman, D. C., Scolyer, R. A., Mann, G. J., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.05.011 · Cited by 102
Sun, X., Li, J., Sun, Y., Zhang, Y., Dong, L., Shen, C., Liu, Y., Yang, M., Li, Y., Shen, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10669 · Cited by 103
BRAF V600E mutation in hairy cell leukemia: from bench to bedside
Falini, B., Martelli, M. P., & Tiacci, E. (2016) · Blood · doi:10.1182/blood-2016-07-418434 · Cited by 102
Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
Ensslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.038 · Cited by 102
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
Vultur, A., Villanueva, J., Krepler, C., Rajan, G., Chen, Q., Xiao, M., Li, L., Gimotty, P. A., Wilson, M. A., Hayden, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.131 · Cited by 101
B-Raf and the inhibitors: from bench to bedside
Huang, T., Karsy, M. J., Zhuge, J., Zhong, M., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-30 · Cited by 103
Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A. K., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 102
Li, Z., Jiang, K., Zhu, X., Lin, G., Song, F., Zhao, Y., Piao, Y., Liu, J., Cheng, W., Bi, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.015 · Cited by 102
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0022 · Cited by 102
Self-citationKorkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
Huang, S. K., & Hoon, D. S. �. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.008 · Cited by 99
Rostami, E., Nyström, P. W., Libard, S., Wikström, J., Casar‐Borota, O., & Gudjonsson, O. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-017-3311-0 · Cited by 99
Ferroptosis in life: To be or not to be
Xu, L., Liu, Y., Chen, X., Zhong, H., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114241 · Cited by 100
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
